Caladrius Biosciences (CLBS) Receives Coverage Optimism Score of 0.18
Media coverage about Caladrius Biosciences (NASDAQ:CLBS) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Caladrius Biosciences earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.7118448267879 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Caladrius Biosciences, Inc. (NASDAQ:CLBS) Experiences Lighter than Average Trading Volume – First News 24 (firstnewspaper24.com)
- Caladrius Biosciences to Participate at the 2017 Cell & Gene Meeting on the Mesa – Markets Insider (markets.businessinsider.com)
- Zacks Investment Research Upgrades Caladrius Biosciences, Inc. (CLBS) to Buy (americanbankingnews.com)
- Caladrius Biosciences, Inc. (CLBS) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
A number of analysts recently commented on CLBS shares. ValuEngine upgraded shares of Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research note on Tuesday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Caladrius Biosciences in a research note on Friday, July 21st.
Shares of Caladrius Biosciences (NASDAQ:CLBS) opened at 3.58 on Monday. Caladrius Biosciences has a 1-year low of $2.65 and a 1-year high of $7.79. The company’s 50 day moving average price is $4.05 and its 200-day moving average price is $4.51.
Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.08. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 180.68%. Analysts expect that Caladrius Biosciences will post ($2.42) EPS for the current year.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Stock Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related stocks with our FREE daily email newsletter.